MARTEK BIOSCIENCES (MATK) – Analyst Comments
-
Canaccord Genuity Moves Rating on Martek Biosciences (MATK) to Tender; DSM Sees the Value Shareholders Don't
-
Needham & Company Maintains a 'Buy' on Martek Biosciences (MATK); F4Q10 Financial Results Easily Top Estimates
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to MATK Stock Lookup